Clinical Significance of Endothelin-1 And C Reaction Protein in Restenosis After the Intervention of Lower Extremity Arteriosclerosis Obliterans

Reference

• Ku A, Nagler W. Arteriosclerosis obliterans. Postgraduate Med. 1995;98(5):203. doi:10.1080/00325481.1995.11946080.
   PubMed Web of Science ®Google Scholar
• Liu J, Li W, Wang S, et al. MiR-142-3p attenuates the migration of CD4+ T Cells through regulating actin cytoskeleton via RAC1 and ROCK2 in arteriosclerosis obliterans. Plos One. 2014;9(4):e95514. doi:10.1371/journal.pone.0095514.
   PubMed Web of Science ®Google Scholar
• Shima A, Miyamoto M, Kubota Y, et al. Beraprost sodium protects against diabetic nephropathy in patients with arteriosclerosis obliterans: a prospective, randomized, open-label study. J Nippon Med Sch.. 2015;82(2):84–91. doi:10.1272/jnms.82.84.
   PubMed Web of Science ®Google Scholar
• Otsuka T, Arai M, Sugimura K, et al. Preoperative sepsis is a predictive factor for 30-day mortality after major lower limb amputation among patients with arteriosclerosis obliterans and diabetes. J Orthop Sci. 2019. doi:10.1016/j.jos.2019.05.017.
   Web of Science ®Google Scholar
• Jin P, Luxiang C. Clinical research of angioplasty and stent implantation in the treatment of lower limb atherosclerosis obliterans. Heart. 2011;97(Suppl 3):A156–A. doi:10.1136/heartjnl-2011-300867.455.
   Google Scholar
• Lou X, Yu Z, Yang X, et al. Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll‐like receptor 4/NF‐κB signaling pathway. Exp Ther Med.. 2019;18(3):1619–1626. doi:10.3892/etm.2019.7726.
   PubMed Web of Science ®Google Scholar
• Nakajima F, Morimoto S, Yurugi T, et al. Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study. Int J Artif Organs. 2012;35(11):981–985. doi:10.1177/039139881203501103.
   PubMed Web of Science ®Google Scholar
• Nomura S, Taniura T, Shouzu A, et al. Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study). Vasc Health Risk Manag. 2018;14:225. doi:10.2147/VHRM.S171143.
   PubMed Web of Science ®Google Scholar
• Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004;172(1):95–105. doi:10.1016/S0021-9150(03)00204-1.
   PubMed Web of Science ®Google Scholar
• Carreira JM, Reyes R, Gude F, et al. Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. Minim Invas Ther. 2008;17(1):34–42. doi:10.1080/13645700701800343.
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Hirano K, Iida O, et al. Five-year outcomes of self-expanding nitinol stent implantation for chronic total occlusion of the superficial femoral and proximal popliteal artery. Cathet Cardiovasc Intervent.. 2013;82(3):E251–E6. doi:10.1002/ccd.24935.
   PubMed Web of Science ®Google Scholar
• Chen Z, Yang Y-G. The treatment choice of arteriosclerosis obliterans in-stent restenosis]. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2010;48(4):248.
   PubMedGoogle Scholar
• Kuznetsov MR, Komov KV, Tepliakov SA, et al. [Current problems status of restenosis after reconstructive interventions on the pelvic and lower-limb arteries in patients with atherosclerosis obliterans]. Angiologii͡a i sosudistai͡a khirurgii͡a = Angiology and vascular surgery. 2009;15((4):145–151.
   PubMedGoogle Scholar
• Munkhaugen J, Otterstad JE, Dammen T, et al. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. Eur J Prev Cardiol.. 2018;25(9):923–931 doi:10.1177/2047487318768940.
   PubMed Web of Science ®Google Scholar
• Schooling CM, Kodali H, Li S, et al. ET (Endothelin)-1 and ischemic heart disease: a mendelian randomization study. J Thromb Haemost. 2018;16(11):2270.
   PubMed Web of Science ®Google Scholar
• DuBrock HM, AbouEzzeddine OF, Redfield MM. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PloS one. 2018;13(8):e0201836. doi:10.1371/journal.pone.0201836.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y-J, Wang X, et al. PKC-mediated Endothelin-1 expression in endothelial cell promotes Macrophage activation in atherogenesis. Am J Hypertens. 2019;32(9):880. doi:10.1093/ajh/hpz069.
   PubMed Web of Science ®Google Scholar
• Rencüzoğulları İ, Karakoyun S, Karabağ Y, et al. Prognostic efficacy of C-reactive protein/albumin ratio in ST elevation myocardial infarction. Scand Cardiovasc J. 2019;53(2):83–90. doi:10.1080/14017431.2019.1590628.
   PubMed Web of Science ®Google Scholar
• Pernow J, Shemyakin A, Böhm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci. 2012;91(13-14):507–516. doi:10.1016/j.lfs.2012.03.029.
   PubMed Web of Science ®Google Scholar
• Kablak-Ziembicka A, Przewlocki T, Sokołowski A, et al. Carotid intima-media thickness, hs-CRP and TNF-α are ly associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis. 2011;214(1):185–190. doi:10.1016/j.atherosclerosis.2010.10.017.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society. J Vasc Interventional Radiol. 2006;47(6):e1–e192.
   Google Scholar
• Lu H, Guo P. [Plasma heparin cofactor II activity correlates with the incidence of in-stent restenosis after the intervention of arteriosclerosis obliterans in lower extremity]. J Central South Univ. 2015;40(2):177–181.
   Google Scholar
• Li H, Gui H, Yuan G, et al. Increased plasma olfactomedin 2 after interventional therapy is a predictor for restenosis in lower extremity arteriosclerosis obliterans patients. Scand J Clin Lab Invest. 2018;78(4):269. doi:10.1080/00365513.2018.1452287.
   PubMed Web of Science ®Google Scholar
• Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013;168(6):5126–5134. doi:10.1016/j.ijcard.2013.07.113.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Choi MJ, Lee JH, et al. Extracellular fluid/intracellular fluid volume ratio as a novel risk indicator for all-cause mortality and cardiovascular disease in hemodialysis patients. Plos One. 2017;12(1):e0170272. doi:10.1371/journal.pone.0170272.
   PubMed Web of Science ®Google Scholar
• Morrison M, Heijden RVD, Heeringa P, et al. Epicatechin attenuates atherosclerosis and exerts anti-inflammatory effects on diet-induced human-CRP and NFκB in vivo. Atherosclerosis. 2014;233(1):149–156. doi:10.1016/j.atherosclerosis.2013.12.027.
   PubMed Web of Science ®Google Scholar
• Schneider S, Spinner CD, Cassese S, et al. Association of increased CD8 and persisting CRP levels with restenosis in HIV patients after coronary stenting: the ISAR HIV study. Aids. 2016;30(9):1413. doi:10.1097/QAD.0000000000001063.
   PubMed Web of Science ®Google Scholar
• Paradis P, Idris-Khodja N, Mian MOR, et al. Remodeling of endothelial function in atherosclerotic mice overexpressing endothelin-1 restricted to endothelium. Life Sci. 2013;93(25-26):e36–e. doi:10.1016/j.lfs.2013.12.128.
   Google Scholar
• Novo G, Sansone A, Rizzo M, et al. High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: a 20-year prospective study. J. Cardiovasc Med. 2014;15(9):696. doi:10.2459/JCM.0000000000000121.
   Google Scholar
• Paradis P, Ouerd S, Idris-Khodja N, et al. Endothelin-1 Exaggerates Type-1 Diabetes-Accelerated Atherosclerosis Through NADPH Oxidase 1. Hypertension. 2017;70(suppl_1):A080–A.
   Google Scholar